20 marzo 2015
Regarding Sipuleucel-T for use in prostate cancer, information submitted by the drug manufacturer provided better evidence on mortality. However, it is not possible to exactly estimate the extent of added benefit.
http://feeds.sciencedaily.com/~r/sciencedaily/~3/mB0fTwsnbwc/150320101739.htm
